Concepedia

Publication | Open Access

Engineered Anti‐GPC3 Immunotoxin, HN3‐ABD‐T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention

DOIFull Paper Access

60

Citations

39

References

2019

Year

Bryan D. Fleming, Daniel J. Urban, Matthew D. Hall, Thomas Longerich, Tim F. Greten, Ira Pastan, Mitchell Ho
Hepatology

Abstract

These data indicate that ABD-containing deimmunized HN3-T20 immunotoxins are high-potency therapeutics ready to be evaluated in clinical trials for the treatment of liver cancer.

References

YearCitations

Page 1